Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1544610

registered interest
date	22/11/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what proportion of severe asthma patients have been prescribed a biologic in the last 12 months.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	93515
answer	answer is ministerial correction date of answer 29/11/2022 answer text <p>The information on the proportion of severe asthma patients prescribed a biologic is not held in the format requested. However, 3,396 patients commenced a new biologic therapy for severe asthma in the last year. All those patients considered to benefit from a biologic treatment by a specialist severe asthma team will have received the treatment.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately grouped question UIN 93516 question first answered 29/11/2022 15:37:05 answering member 4527 label Biography information for Helen Whately
tabling member	4034 label Biography information for Yvonne Fovargue

1544613

registered interest
date	22/11/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many severe asthma patients were refused biologic treatment in the last 12 months.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	93516
answer	answer is ministerial correction date of answer 29/11/2022 answer text <p>The information on the proportion of severe asthma patients prescribed a biologic is not held in the format requested. However, 3,396 patients commenced a new biologic therapy for severe asthma in the last year. All those patients considered to benefit from a biologic treatment by a specialist severe asthma team will have received the treatment.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately grouped question UIN 93515 question first answered 29/11/2022 15:37:05 answering member 4527 label Biography information for Helen Whately
tabling member	4034 label Biography information for Yvonne Fovargue

1491402

registered interest
date	21/07/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, If he will include metrics on the uptake of biologics for severe asthma in the update to the NHS Long Term Plan.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	41994
answer	answer is ministerial correction date of answer 05/09/2022 answer text <p>The Department and NHS England are currently reviewing delivery of the commitments made in the NHS Long Term Plan, including those relating to respiratory outcomes. The update to the NHS Long Term Plan will be published later this year.</p><p>There are no current plans to include metrics measuring uptake of biologics in the NHS Long Term Plan update. However, pathways to biologic therapy are being streamlined, including through the Accelerated Access Collaborative’s work to improve the identification of patients in primary and secondary care settings for referrals to assess suitability to receive biologic treatment.</p> answering member constituency Chichester answering member printed Gillian Keegan grouped question UIN 41993 question first answered 05/09/2022 11:27:51 answering member 4680 label Biography information for Gillian Keegan
tabling member	4034 label Biography information for Yvonne Fovargue

1456349

registered interest
date	31/03/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of patients who are eligible for biologic treatment for severe asthma who are not currently accessing it.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	151058
answer	answer is ministerial correction date of answer 19/04/2022 answer text <p>The NHS England and NHS Improvement Accelerated Access Collaborative (AAC) on Improving Access to Biologic Therapy estimates that approximately 200,000 or 5% of patients with asthma have severe asthma. Of these patients, the AAC estimates that between 50,000 to 100,000 may be eligible for biologic therapy, with approximately 11,000 patients receiving this treatment. The AAC aims to improve the identification of these patients in primary and secondary care settings, to allow referrals to specialist severe asthma centres to determine their suitability for biologic treatment.</p><p>No specific estimate of the number of patients awaiting an appointment at a severe asthma centre has been made as this information is not collected in the format requested. No specific assessment has been made of the effectiveness of home administration of biologics for severe asthma. The National Institute for Health and Care Excellence’s COVID-19 rapid guideline on severe asthma promoted the use of home administration for biologic treatments to maintain access and reduce risks to patients of COVID-19 exposure. While we are ensuring that patients who are eligible for this treatment are able to access it, there are no plans to extend the eligibility criteria.</p> answering member constituency Chichester answering member printed Gillian Keegan grouped question UIN 151059 151060 question first answered 19/04/2022 11:47:25 answering member 4680 label Biography information for Gillian Keegan
tabling member	4034 label Biography information for Yvonne Fovargue

1456351

registered interest
date	31/03/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of home administration of biologics for severe asthma; and whether he has plans to extend that treatment.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	151060
answer	answer is ministerial correction date of answer 19/04/2022 answer text <p>The NHS England and NHS Improvement Accelerated Access Collaborative (AAC) on Improving Access to Biologic Therapy estimates that approximately 200,000 or 5% of patients with asthma have severe asthma. Of these patients, the AAC estimates that between 50,000 to 100,000 may be eligible for biologic therapy, with approximately 11,000 patients receiving this treatment. The AAC aims to improve the identification of these patients in primary and secondary care settings, to allow referrals to specialist severe asthma centres to determine their suitability for biologic treatment.</p><p>No specific estimate of the number of patients awaiting an appointment at a severe asthma centre has been made as this information is not collected in the format requested. No specific assessment has been made of the effectiveness of home administration of biologics for severe asthma. The National Institute for Health and Care Excellence’s COVID-19 rapid guideline on severe asthma promoted the use of home administration for biologic treatments to maintain access and reduce risks to patients of COVID-19 exposure. While we are ensuring that patients who are eligible for this treatment are able to access it, there are no plans to extend the eligibility criteria.</p> answering member constituency Chichester answering member printed Gillian Keegan grouped question UIN 151058 151059 question first answered 19/04/2022 11:47:25 answering member 4680 label Biography information for Gillian Keegan
tabling member	4034 label Biography information for Yvonne Fovargue

1353444

registered interest
date	07/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the size of the eligible population among severe asthma suffers for biologic treatments.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	44318
answer	answer is ministerial correction date of answer 16/09/2021 answer text <p>No estimate has been made and information on the number of severe asthma patients are receiving biologic therapies is not available in the format requested.</p><p> </p><p> </p><p>Clinicians are responsible for making prescribing decisions for their patients, taking into account the National Institute for Health and Care Excellence’s technology appraisals and guidance on management of asthma and the local commissioning decisions. Prescribing of biologics for severe asthma is co-ordinated through severe asthma centre multi-disciplinary teams to ensure current treatments are optimised and all appropriate treatments are considered with use of biologics as part of the treatment review for each patient.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 44319 44320 question first answered 16/09/2021 15:01:18 answering member 4380 label Biography information for Jo Churchill
tabling member	4034 label Biography information for Yvonne Fovargue

1353445

registered interest
date	07/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many severe asthma patients are receiving biologic therapies through (a) the severe asthma networks and (b) other services.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	44319
answer	answer is ministerial correction date of answer 16/09/2021 answer text <p>No estimate has been made and information on the number of severe asthma patients are receiving biologic therapies is not available in the format requested.</p><p> </p><p> </p><p>Clinicians are responsible for making prescribing decisions for their patients, taking into account the National Institute for Health and Care Excellence’s technology appraisals and guidance on management of asthma and the local commissioning decisions. Prescribing of biologics for severe asthma is co-ordinated through severe asthma centre multi-disciplinary teams to ensure current treatments are optimised and all appropriate treatments are considered with use of biologics as part of the treatment review for each patient.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 44318 44320 question first answered 16/09/2021 15:01:18 answering member 4380 label Biography information for Jo Churchill
tabling member	4034 label Biography information for Yvonne Fovargue

1353446

registered interest
date	07/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the geographical variation in the prescribing of biologics for severe asthma.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	44320
answer	answer is ministerial correction date of answer 16/09/2021 answer text <p>No estimate has been made and information on the number of severe asthma patients are receiving biologic therapies is not available in the format requested.</p><p> </p><p> </p><p>Clinicians are responsible for making prescribing decisions for their patients, taking into account the National Institute for Health and Care Excellence’s technology appraisals and guidance on management of asthma and the local commissioning decisions. Prescribing of biologics for severe asthma is co-ordinated through severe asthma centre multi-disciplinary teams to ensure current treatments are optimised and all appropriate treatments are considered with use of biologics as part of the treatment review for each patient.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 44318 44319 question first answered 16/09/2021 15:01:18 answering member 4380 label Biography information for Jo Churchill
tabling member	4034 label Biography information for Yvonne Fovargue

1353447

registered interest
date	07/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what help is available for asthma sufferers to enable them to continue to self-administer their medication due to the pressures on the NHS during the covid-19 outbreak.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	44321
answer	answer is ministerial correction date of answer 10/09/2021 answer text <p>Specialist respiratory services for severe asthma, along with urgent and emergency treatment for other serious complaints, have continued throughout the COVID-19 outbreak. In most cases people with severe asthma have been able to receive their medication at home instead of having to attend hospital.</p><p>The National Institute for Health and Care Excellence COVID-19 rapid guideline on severe asthma promoted the use of home delivery for biologic treatments to maintain access and reduce the risks to patients of COVID-19 exposure. The NHS England severe asthma ‘Accelerated Access Collaborative’ will continue to focus on the area of home administration.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 10/09/2021 13:13:49 answering member 4380 label Biography information for Jo Churchill
tabling member	4034 label Biography information for Yvonne Fovargue

1348831

registered interest
date	20/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to support clinical choice in asthma treatment in the provision of biologic treatments, as recommended in the APPG report, entitled Improving Asthma Outcomes in the UK.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	36617
answer	answer is ministerial correction date of answer 27/07/2021 answer text <p>There has been significant increase in the use of biologics in the last three years. The decision to start a biologic treatment for asthma is made by specialist severe asthma multi-disciplinary teams (MDT) based in severe asthma centres on clinical grounds. The MDT considers all aspects of the patients’ illness, efficacy of current treatments and other treatment options. Patients receiving biologics are closely monitored to ensure that they are receiving the right treatment to help manage their symptoms.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 27/07/2021 14:04:10 answering member 4380 label Biography information for Jo Churchill
tabling member	4034 label Biography information for Yvonne Fovargue